Emerging as one of the most underdiagnosed conditions on the medical front, pulmonary hypertension (PH) is characterized by increased pressure in the pulmonary arteries of at least double normal pressures: >25 mm Hg at rest and >30 mm during exercise. The disease process results in narrowing and stiffening of the pulmonary arterial lumen walls and causes an obstruction of blood flow, which (over time) leads to right-sided heart failure.
The New York Heart Association Functional Classification System assigns four categories to classify the extent of the resultant heart failure (see Heart Failure in Part 2), and this information is frequently used to estimate prognosis and determine eligibility for clinical trials. Symptoms of PH include dyspnea, fatigue, chest pain, tachycardia, syncope, peripheral edema, and possibly cyanosis.
While definitive diagnosis is difficult, the “gold standard” for identification is right-sided cardiac catheterization. Treatment is aimed at slowing disease progression and decreasing the workload of the heart by allowing blood to flow more easily through the pulmonary arteries. The IV drug Flolan (epoprostenon) and the IV/SQ drug Remodulin (treprostinil) are commonly used, although there are many other drugs available. More recently, the FDA has approved Tyvaso (treprostinil) Inhalation Solution for treatment, administered via a specialized inhalation system.
noun high blood pressure in the blood vessels supplying blood to the lungs ...
Introduction Pulmonary hypertension is defined as a mean pulmonary artery pressure of greater than 25 mm Hg at rest or 30 mm Hg with...
Giorgio Della Rocca Email: firstname.lastname@example.org Definition Pulmonary hypertension (PH) is defined as an increase in mean pulmonary arteri